These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 17018257)

  • 1. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
    Dessalew N; Patel DS; Bharatam PV
    J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3β inhibitors.
    Akhtar M; Bharatam PV
    Chem Biol Drug Des; 2012 Apr; 79(4):560-71. PubMed ID: 22168279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies.
    Patel DS; Bharatam PV
    Eur J Med Chem; 2008 May; 43(5):949-57. PubMed ID: 17707953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.
    He Q; Han C; Li G; Guo H; Wang Y; Hu Y; Lin Z; Wang Y
    Comput Biol Chem; 2020 Oct; 88():107328. PubMed ID: 32688011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
    Xiao J; Guo Z; Guo Y; Chu F; Sun P
    Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
    Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
    J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D-QSAR and docking studies of selective GSK-3beta inhibitors. Comparison with a thieno[2,3-b]pyrrolizinone derivative, a new potential lead for GSK-3beta ligands.
    Lescot E; Bureau R; Sopkova-de Oliveira Santos J; Rochais C; Lisowski V; Lancelot JC; Rault S
    J Chem Inf Model; 2005; 45(3):708-15. PubMed ID: 15921460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3.
    Potshangbam AM; Tanneeru K; Reddy BM; Guruprasad L
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7219-23. PubMed ID: 22018459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico approaches to develop new phenyl-pyrimidines as glycogen synthase kinase 3 (GSK-3) inhibitors with halogen-bonding capabilities: 3D-QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies.
    Cabezas D; Mellado G; Espinoza N; Gárate JA; Morales C; Castro-Alvarez A; Matos MJ; Mellado M; Mella J
    J Biomol Struct Dyn; 2023; 41(22):13250-13259. PubMed ID: 36718094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QSAR, docking, and CoMFA studies of GSK3 inhibitors.
    García I; Fall Y; Gómez G
    Curr Pharm Des; 2010; 16(24):2666-75. PubMed ID: 20642432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking-based 3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) study on hydroquinoline and thiazinan-4-one derivatives as selective COX-2 inhibitors.
    Dowlati Beirami A; Hajimahdi Z; Zarghi A
    J Biomol Struct Dyn; 2019 Jul; 37(11):2999-3006. PubMed ID: 30035675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D QSAR pharmacophore, CoMFA and CoMSIA based design and docking studies on phenyl alkyl ketones as inhibitors of phosphodiesterase 4.
    Gaurav A; Singh R
    Med Chem; 2012 Sep; 8(5):894-912. PubMed ID: 22741782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS; Balaji B; Rani P; Ramanathan M
    J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular docking, 3D QSAR and dynamics simulation studies of imidazo-pyrrolopyridines as janus kinase 1 (JAK 1) inhibitors.
    Itteboina R; Ballu S; Sivan SK; Manga V
    Comput Biol Chem; 2016 Oct; 64():33-46. PubMed ID: 27244086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods.
    Pourbasheer E; Aalizadeh R
    SAR QSAR Environ Res; 2016 May; 27(5):385-407. PubMed ID: 27228480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking.
    Prasanna S; Daga PR; Xie A; Doerksen RJ
    J Comput Aided Mol Des; 2009 Feb; 23(2):113-27. PubMed ID: 18839067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D QSAR studies on GSK-3 inhibition by aloisines.
    Zeng M; Jiang Y; Zhang B; Zheng K; Zhang N; Yu Q
    Bioorg Med Chem Lett; 2005 Jan; 15(2):395-9. PubMed ID: 15603961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.